$PODD News

Insulet's Q2 2026 Earnings: What to Expect

Insulet Corp (NASDAQ:PODD): A Quality Affordable Growth Stock With Strong Earnings Momentum

Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

Insulet Corporation Partners With Calm To Provide Free Mindfulness Resources Addressing Anxiety And Burnout Among People Living With Diabetes

Insulet Corporation (PODD) Fell Along with Broad Medtech Sector

Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago

Truist Securities Maintains Buy on Insulet, Lowers Price Target to $210

RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $245

Stifel Maintains Buy on Insulet, Lowers Price Target to $225

Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47%

Insulet (PODD) Launches Omnipod 5 In Spain, Is The Stock Cheap?

Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut?

Citigroup Maintains Neutral on Insulet, Raises Price Target to $172

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Why Insulet (PODD) Could Beat Earnings Estimates Again

Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target

FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports

Evercore ISI Group Maintains Outperform on Insulet, Lowers Price Target to $180

Insulet Launches Its Omnipod 5 Automated Insulin Delivery And Proprietary Data Management System Omnipod Discover In Spain

Insulet Recalls Omnipod Pods After Insulin-Delivery Failure Risk Identified, FDA Says